Matthew Goetz, MD | Authors

Articles

ELAINE-1 Trial Examines Lasofoxifene in ESR1+, ER+/HER2- Breast Cancer

November 10, 2022

Matthew P. Goetz, MD, discusses the background of the ELAINE-1 study examining lasofoxifene in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer harboring estrogen receptor 1 mutations.